SCHEMBL539031

SCHEMBL539031

c1nnc(-c2cnsn2)s1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464831 0.65
SCHEMBL29913029 0.63 CDK2 (0.36)
SCHEMBL29193359 0.63 CDK2 (0.36)
SCHEMBL19900526 0.62
SCHEMBL9905290 0.61 KDM4E (0.59)
SCHEMBL3263883 0.60 PPARA (0.32)
SCHEMBL4559345 0.58 KMT2A (0.42)
SCHEMBL572719 0.58 PDPK1 (0.45)
SCHEMBL1680218 0.56 CYP2A6 (0.55)
SCHEMBL3140312 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140941-B1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-10-20 EP claimed
CN-114989630-B Negative dichroic dye, preparation method thereof and display device 江苏创拓新材料有限公司 2024-05-28 CN disclosed
CN-114621270-B Condensed ring aromatic compound and application thereof in electroluminescent device 清华大学 2024-04-12 CN disclosed
CN-115850992-B Novel blue dichroic dye and application thereof 江苏创拓新材料有限公司 2023-09-15 CN disclosed
CN-116615038-A Organic electroluminescent device and display device 清华大学 2023-08-18 CN disclosed
EP-3990592-A1 USE OF A TRIAZOLE COMPOUND AS AN ADDITIVE FOR IMPROVING THE ANTI-CORROSION PROPERTIES OF A LUBRICANT COMPOSITION FOR A PROPULSION SYSTEM OF AN ELECTRIC OR HYBRID VEHICLE Total Marketing Services (FR) 2022-05-04 EP disclosed
WO-2020260457-A1 USE OF A TRIAZOLE COMPOUND AS AN ADDITIVE FOR IMPROVING THE ANTI-CORROSION PROPERTIES OF A LUBRICANT COMPOSITION FOR A PROPULSION SYSTEM OF AN ELECTRIC OR HYBRID VEHICLE TOTAL MARKETING SERVICES (FR) 2020-12-30 WO disclosed
EP-2791294-A1 LUBRICATING COMPOSITIONS FOR TRANSMISSIONS Total Raffinage Marketing (FR) 2014-10-22 EP disclosed
WO-2013087889-A1 LUBRICATING COMPOSITIONS FOR TRANSMISSIONS TOTAL RAFFINAGE MARKETING (FR) 2013-06-20 WO disclosed
EP-1836169-B9 COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS KINEX PHARMACEUTICALS LLC (US) 2012-07-04 EP disclosed
EP-1264826-B1 NOVEL IMIDAZOLINE COMPOUNDS BANYU PHARMA CO LTD (JP) 2005-03-30 EP disclosed
US-20040266854-A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto GPC BIOTECH, INC. (US) 2004-12-30 US disclosed
US-20040266853-A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto GPC BIOTECH, INC. (US) 2004-12-30 US disclosed
WO-2004092139-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO GPC BIOTECH, INC. (US) 2004-10-28 WO disclosed
US-6800760-B2 INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE CHIRON CORPORATION 2004-10-05 US disclosed
EP-1446405-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO GPC Biotech Inc. (US) 2004-08-18 EP disclosed
US-20030158418-A1 Novel imidazonline compounds MSD K.K. (JP) 2003-08-21 US disclosed
WO-2003033499-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO GPC BIOTECH INC. (US) 2003-04-24 WO disclosed
EP-1264826-A1 NOVEL IMIDAZOLINE COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed
US-4963544-A THIENAMYCIN ANTIBIOTICS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266853-A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto CDK1, CCNO, CCNI FBP1 1178/4885
US-20040266854-A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto CDK1, CCNO, CCNI FBP1 1178/4885
US-20030158418-A1 Novel imidazonline compounds NPY1R, NPY2R, GPR119 FBP1 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.